Eli Lilly buys itself an antibody R&D platform from Tillman Gerngross’s Adimab
Eli Lilly has just executed on a turnkey antibody platform deal with Tillman Gerngross’s Adimab.
We don’t know the deal terms, but Lilly turned to the antibody shop in New Hampshire for the platform tech, now designated for its R&D groups in San Diego and New York. Lilly also gets an antibody library as well as a license to use the platform in any way it likes.
The two companies have been working together from the early days at Adimab, beginning in 2010.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
